Neuraly, Inc. is a biotechnology company focused on developing immunotherapies for neurodegenerative diseases, with a primary focus on Parkinson's disease (PD) and Alzheimer's disease (AD). The company's lead candidate, NLY01 (also known as Pegcreatecan), is a novel glucagon-like peptide-1 receptor (GLP-1R) agonist designed to target neuroinflammation and [alpha-synuclein](/proteins/alpha-synuclein) pathology[@neuraly][@neuralya].
Neuraly's platform is based on targeting neuroinflammation through [GLP-1 receptor](/entities/glp1-receptor) modulation. The company developed NLY01 as a long-acting GLP-1R agonist that penetrates the [blood-brain barrier](/entities/blood-brain-barrier) to exert neuroprotective effects[@neuralya].
Mechanism of Action
NLY01 works through multiple pathways:
GLP-1 Receptor Activation: Binds to GLP-1R on neuronal and glial cells, triggering intracellular signaling cascades that promote cell survival
Neuroinflammation Reduction: Inhibits microglial activation and reduces pro-inflammatory cytokine production
Alpha-synuclein Modulation: Reduces alpha-synuclein aggregation and promotes clearance of toxic oligomers
Mitochondrial Protection: Enhances mitochondrial function and reduces oxidative stress
Pipeline
NLY01 (Lead Candidate)
...
Overview
Neuraly, Inc. is a biotechnology company focused on developing immunotherapies for neurodegenerative diseases, with a primary focus on Parkinson's disease (PD) and Alzheimer's disease (AD). The company's lead candidate, NLY01 (also known as Pegcreatecan), is a novel glucagon-like peptide-1 receptor (GLP-1R) agonist designed to target neuroinflammation and [alpha-synuclein](/proteins/alpha-synuclein) pathology[@neuraly][@neuralya].
Neuraly's platform is based on targeting neuroinflammation through [GLP-1 receptor](/entities/glp1-receptor) modulation. The company developed NLY01 as a long-acting GLP-1R agonist that penetrates the [blood-brain barrier](/entities/blood-brain-barrier) to exert neuroprotective effects[@neuralya].
Mechanism of Action
NLY01 works through multiple pathways:
GLP-1 Receptor Activation: Binds to GLP-1R on neuronal and glial cells, triggering intracellular signaling cascades that promote cell survival
Neuroinflammation Reduction: Inhibits microglial activation and reduces pro-inflammatory cytokine production
Alpha-synuclein Modulation: Reduces alpha-synuclein aggregation and promotes clearance of toxic oligomers
Mitochondrial Protection: Enhances mitochondrial function and reduces oxidative stress
NLY01 completed Phase 1 trials demonstrating safety and tolerability in healthy volunteers and patients with Parkinson's disease[@glp].
Phase 2 Trials
The company advanced NLY01 into Phase 2 clinical trials for Parkinson's disease to evaluate efficacy and safety. The trial aimed to assess motor symptoms, cognitive function, and biomarkers of neuroinflammation[@neuralya].
Potential Applications
Beyond Parkinson's disease, NLY01 may have applications in:
Other neurodegenerative disorders with neuroinflammatory components
Science and Research
Preclinical Data
Preclinical studies demonstrated that NLY01:
Reduced alpha-synuclein aggregation in cellular and animal models[@neuraly]
Improved motor performance in Parkinson's disease models
Decreased microglial activation and neuroinflammation markers
Protected dopaminergic [neurons](/entities/neurons) from degeneration
GLP-1R Agonists in Neurodegeneration
The development of NLY01 is part of a broader therapeutic approach using GLP-1 receptor agonists for neuroprotection. Other companies developing similar approaches include:
Neuraly has received funding from venture capital investors to support its clinical development programs. The company operates as a private entity and may seek additional financing or partnership opportunities to advance its pipeline[@neuraly].